FDA experts back GSK's new malaria drug; Sangamo's newly minted CTO jumps to biotech upstart
→ GlaxoSmithKline has turned the final corner in the race to gain an FDA approval for tafenoquine, a new treatment for patients with P. vivax malaria. A panel of outside experts voted 13 to 0 to endorse the drug and recommend an approval. That comes on top of an internal review that also backed the application. “If approved, tafenoquine would be the first new medicine for this indication in more than 60 years,” says Pauline Williams, head of Global Health R&D at GSK.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.